Navigation Links
Genoptix, Inc. to Announce Fourth Quarter and Full-Year 2009 Financial Results
Date:2/4/2010

CARLSBAD, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a provider of personalized diagnostic services, announced today that it expects to report its financial results for the fourth quarter and full-year 2009 after closing of the NASDAQ Global Select Market on Thursday, February 25, 2010.

A conference call hosted by President and CEO, Tina S. Nova, Ph.D., and other members of senior management will take place on the same day at 2:00pm PST (5:00pm EST) and will be webcast live on the Genoptix website.  

To access the live conference call via phone, dial 866-578-5784 in the U.S. or Canada and 617-213-8056 for international callers.  Please specify to the operator that you would like to join the "Genoptix Fourth  Quarter and Full-Year 2009 Earnings Conference Call." The participant code for the call is 55554709. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, March 4, 2010.  Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 41371647.

The conference call will be webcast live on the Internet and is accessible through the "Investors" section of the Genoptix website at www.genoptix.com, or by accessing the external website, www.fulldisclosure.com.  To participate in the webcast, please connect to the Genoptix website several minutes prior to the start time to register, download and install any necessary software that may be required.  An online replay is planned to follow shortly after and will be available until Thursday, March 4, 2010.  

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports.  Its primary diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Founded in 1999, Genoptix completed its initial public offering in November 2007 and is headquartered in Carlsbad, California.  For more information, please visit www.genoptix.com.

Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE Genoptix, Inc.

RELATED LINKS
http://www.genoptix.com

'/>"/>

SOURCE Genoptix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation Analysis for MPD at 49th Annual American Society of Hematology (ASH) Meeting
2. Genomic Health Announces Year-End 2009 Financial Results
3. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
4. Foundation Radiology Group Announces FRG Molecular Imaging Division, Led By Todd M. Blodgett, M.D.
5. Pulse Systems Announces New Sales Representation in the Western United States
6. HealthSport, Inc. Announces Issuance of Mexican Patent
7. The International Negative Pressure Wound Therapy Expert Panel to Announce Results of Inaugural Symposium in Hamburg
8. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
9. Vermillion Announces the Reappointment of Officers and Confirmation of Director
10. Upsher-Smith Announces New Formulation of PreNexa(R) Prenatal Vitamins
11. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  Echo Therapeutics, ... device company focused on non-invasive continuous glucose ... today announced that it will host a ... 17, 2015 at 9:00 a.m. Eastern Time ... its corporate strategy, advancements in its CGM ...
(Date:2/8/2016)... , Feb. 8, 2016 ... the "Global Skin Protective Equipment Market 2016-2020" ... --> http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced the addition ... 2016-2020" report to their offering. ... ) has announced the addition of the ...
(Date:2/8/2016)... , Feb. 8, 2016   HighPoint ... November Research Group (NRG),s pharmacovigilance technology services division.  ... consulting services and an Oracle Argus Specialized partner, ... to Life Sciences companies. --> ... expands HighPoint,s life sciences capabilities and provides a ...
Breaking Medicine Technology:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... offices in Houma, LA, celebrates the beginning of a new charity campaign. As ... assist Court Appointed Special Advocates (CASA). In the belief that children deserve a ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your clothes are ... alone. According to the Center for Disease Control and Prevention (CDC), 34.9% of U.S. ... certain types of cancer, some of the leading causes of preventable death. February ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency ... Venice, FL area, has initiated a fundraiser for a two year old little ... days after Christmas. To support this beautiful child who is facing life’s journey ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic ... of women and men with eating disorders report a history of trauma, research ... development of an eating disorder. , At the 2016 iaedp Symposium, the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Association of ... AHCC and the Home Health and Hospice ICD-10 Transition Workgroup are working closely ... coding guidance and clarifications, to address concerns over the use of 'A' as ...
Breaking Medicine News(10 mins):